Inflammation-driven Oncogenesis: Precision Medicine and Immunotherapeutic Strategies

Cancer remains a significant global health burden, placing immense pressure on healthcare systems and putting huge pressure on the healthcare system. There are multiple driving forces, and increasing attention has been gained over the past two decades regarding chronic inflammation, which represents a pivotal factor owing to its ability to establish or maintain an environment that is permissive for tumor initiation, growth, and progression. This review details the interplay between inflammation and cancer by highlighting how chronic inflammation fuels oncogenesis by promoting genetic instability, immune evasion, and a setting rich in pro-tumorigenic signaling. This review explains how various inflammatory mediators, including cytokines and transcription factors, can potentially create tumor microenvironments by drawing on case studies and recent research data. Furthermore, this article provides insights into the molecular mechanisms of Nuclear Factor Kappa B (NF-κB)-regulated pathways and inflammasomes and provides essential molecular links between inflammation and tumorigenesis. Furthermore, novel therapeutic approaches using nanotechnology and immunotherapy are also discussed. Nanotechnology offers precise drug delivery with increased targeting to tumor sites, whereas immunotherapy, including immune checkpoint inhibitors, attempts to restore the functionality of the immune system to recognize and destroy cancer cells. Thus, a combination of these approaches represents a promising new frontier in cancer treatment that addresses both the inflammatory and immune dimensions of oncogenesis. This review highlights the importance of integrating molecular insights into novel therapeutic strategies to address the dual challenges associated with chronic inflammation and cancer. Their development could lead to significant improvements in patient outcomes and reduce global cancer burden.